ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "fibrosis and scleroderma"

  • Abstract Number: 116 • 2018 ACR/ARHP Annual Meeting

    Identifying Matricellular Protein CYR61 As a Potential Anti-Fibrotic and Pro-Angiogenic Mediator in Scleroderma

    Pei-Suen Tsou1, Dinesh Khanna2 and Amr H Sawalha1, 1Division of Rheumatology, University of Michigan, Ann Arbor, MI, 2Division of Rheumatology, University of Michigan Scleroderma Program, Ann Arbor, MI

    Background/Purpose: Vascular abnormalities represent a fundamental event in the pathogenesis of scleroderma (SSc) in that endothelial cell (EC) damage triggers a self-fueling process ending in…
  • Abstract Number: 131 • 2018 ACR/ARHP Annual Meeting

    Myofibroblast Cells Expression of CD248 May Contribute to Exacerbate Microvascular Damage during Systemic Sclerosis

    Paola Di Benedetto1, Rebecca Ross2, Paola Cipriani1, Filomena Esteves3, Vasiliki Liakouli1, Piero Ruscitti1, Francesco Carubbi1, Onorina Berardicurti1, Noemi Panzera1, Salvatore Di Bartolomeo1, Chiara Galloni4, Georgia Mavria4, Francesco Del Galdo2 and Roberto Giacomelli1, 1Department of Applied Clinical Sciences and Biotechnology, Rheumatology Unit, University of L'Aquila, L'Aquila, Italy, 2Leeds Biomedical Research Centre and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 3Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom, 4Signal Transduction and Tumour Microenvironment Group, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, Italy

    Background/Purpose: Microvascular rarefaction and tissue fibrosis are the hallmarks of Systemic Sclerosis (SSc). CD248, also known as endosialin, is a transmembrane glycoprotein expressed on key…
  • Abstract Number: 1717 • 2018 ACR/ARHP Annual Meeting

    Expert Consensus on the Screening, Treatment, and Management of Patients with Systemic Sclerosis-Interstitial Lung Disease, and the Potential Role of Anti-Fibrotics in a Treatment Paradigm for Systemic Sclerosis-Interstitial Lung Disease: A Delphi Consensus Study

    Dinesh Khanna1,2, Mary Strek3, Brian Southern4, Rajan Saggar5, Vivien Hsu6, Maureen D. Mayes7, Rick Silver8, Virginia D. Steen9, Donald Zoz10 and Franck Rahaghi11, 1Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, 2Division of Rheumatology, University of Michigan, Ann Arbor, MI, 3Pulmonology, University of Chicago, Chicago, IL, 4Pulmonology, Cleveland Clinic Ohio, Cleavland, OH, 5Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 6Rheumatology, Robert Wood Johnson University Scleroderma Program, New Brunswick, NJ, 7Rheumatology, University of Texas Medical School at Houston, Houston, TX, 8Rheumatology, Medical University of SC, Charleston, SC, 9Dept of Rheumatology, Georgetown Univ Medical Center, Washington, DC, 10Pulmonology, Boehringer Ingelheim, Ridgefield, CT, 11Cleveland Clinic Florida Weston, Weston, FL

    Background/Purpose: Systemic sclerosis (SSc), or scleroderma, is a rare, autoimmune, multisystem connective tissue disorder characterized by vascular damage, autoimmunity, and fibrosis of the skin and…
  • Abstract Number: 767 • 2017 ACR/ARHP Annual Meeting

    Elevated MeCP2 Expression in Diffuse Cutaneous Systemic Sclerosis Dermal Fibroblasts Is Associated with Anti-Fibrotic Effects

    Ye He1, Pei-Suen Tsou2, Dinesh Khanna3 and Amr H Sawalha2, 1Rheumatology, University of Michigan, Ann Arbor, MI, 2Division of Rheumatology, University of Michigan, Ann Arbor, MI, 3University of Michigan, Ann Arbor, MI

    Background/Purpose: Systemic Sclerosis (SSc) is a multisystem autoimmune connective tissue disorder characterized by vascular injury and fibrosis of the skin and internal organs. Methyl-CpG-binding protein…
  • Abstract Number: 776 • 2017 ACR/ARHP Annual Meeting

    Circulating Fibrocytes in Systemic Sclerosis Patients and Healthy Subjects: An in Vitro Study

    Maurizio Cutolo1, Paola Montagna2, Stefano Soldano2, Amelia Chiara Trombetta3, Paola Contini4, Vanessa Smith5, Barbara Ruaro2, Alberto Sulli3 and Renata Brizzolara2, 1Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS A.O.U. San Martino-IST, University of Genova, Genoa, Italy, Genoa, Italy, 2Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino, Genoa, Italy, Genoa, Italy, 3Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS A.O.U. San Martino-IST, University of Genova, Genoa, Italy, Genova, Italy, 4Division of Clinical Immunology, Department of Internal Medicine, University of Genova, Genoa, Italy, Genova, Italy, 5Faculty of Internal Medicine, Ghent University, Ghent, Belgium

    Background/Purpose: Circulating fibrocytes seem to exert immunomodulatory effects, expressing class II major histocompatability complex molecules (HLA-DP, -DQ, and -DR) and could have a role in…
  • Abstract Number: 806 • 2016 ACR/ARHP Annual Meeting

    Single Cell Rnaseq Defines a Unique Transcriptome Profile for Myofibroblasts in the Skin of Patients with Systemic Sclerosis

    Robert A. Lafyatis1, Lisa Rice2, Giuseppina Stifano2, Jeff Browning2,3 and Robert W. Simms4, 1Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 2Boston University School of Medicine, Boston, MA, 3Boston university, Cambridge, MA, 4Rheumatology, Boston University School of Medicine, Boston, MA

    Background/Purpose: Fibrosis in systemic sclerosis (SSc), as well as a wide variety of other fibrotic diseases, is largely driven by myofibroblasts. Myofibroblasts are known to…
  • Abstract Number: 1855 • 2016 ACR/ARHP Annual Meeting

    Phosphodiesterase-5 Inhibitors Attenuate Fibrotic Phenotype and Restore Anti-Fibrotic Resopnses of Cutaneous Fibroblasts in Patients with Scleroderma

    Vikas Agarwal1, Mohit kumar Rai1, Vinita Agrawal2, Harshit Singh1 and Saurabh Chaturvedi1, 1Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 2Pathology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, India

    Background/Purpose:  Scleroderma (SSc) is a chronic autoimmune disease, characterized by excessive fibrosis of skin and internal organs due to uncontrolled proliferation of fibroblasts and deposition…
  • Abstract Number: 1856 • 2016 ACR/ARHP Annual Meeting

    Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04755) As a Potential Topical Treatment for Scleroderma

    Vishal Deshmukh1, Allison Hood2, Maureen Ibanez1, Luis Dellamary1, Josh Stewart1, Timothy Seo1, John Hood2 and Yusuf Yazici1, 1Samumed, LLC, San Diego, CA, 2Samumed, LLC (formerly), San Diego, CA

    Background/Purpose: Scleroderma is an autoimmune fibrotic disease, which presents skin manifestations among others. The Wnt pathway plays an important role in inflammation, skin fibrosis, and…
  • Abstract Number: 3264 • 2015 ACR/ARHP Annual Meeting

    Multiplex Serum Protein Analysis in Systemic Sclerosis Defines Potential Anti-Fibrotic Mechanisms and Markers of Response to Hyperimmune Caprine Serum

    Niamh Quillinan1, Kristina E.N. Clark1, Deirdre McIntosh2, Jeffrey Vernes2 and Christopher P. Denton3, 1Rheumatology, UCL Division of Medicine, London, United Kingdom, 2Daval International, London, United Kingdom, 3Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom

    Background/Purpose:   Hyperimmune caprine serum (HICS) administered by subcutaneous injection over 26 weeks has shown benefit for modified Rodnan skin score in diffuse systemic sclerosis…
  • Abstract Number: 771 • 2014 ACR/ARHP Annual Meeting

    Development of a Bifluorescent Lineage Tracker Reporter Mouse Strain to Analyze the Phenotypic Conversion of Endothelial Cells into Myofibroblasts in Vivo. Application to Study the Synergistic Effects of Endothelin-1 on TGF-β1-Induced Endothelial-to-Mesenchymal Transition

    Peter J. Wermuth and Sergio A. Jimenez, Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center,Thomas Jefferson University, Philadelphia, PA

    Background/Purpose: Endothelial-to-mesenchymal transition (EndoMT) may be a crucial pathway in generating activated myofibroblasts, cells that play a pivotal role in the development of tissue and…
  • Abstract Number: 1796 • 2014 ACR/ARHP Annual Meeting

    Autotaxin Is Highly Expressed in Systemic Sclerosis (SSc) Skin, Mediates Dermal Fibrosis Via IL-6, and Is a Target for SSc Therapy

    Flavia V. Castelino1,2, Leaya M. George3, Gretchen Bain4, Lance Goulet5, Robert Lafyatis6 and Andrew M. Tager3,7, 1Rheumatology, Massachusetts General Hospital, Boston, MA, 2Harvard Medical School, Boston, MA, 3Pulmonary Unit, Massachusetts General Hospital, Boston, MA, 4Biology, PharmAkea Pharmaceuticals, San Diego, CA, 5PharmAkea Pharmaceuticals, San Diego, CA, 6Rheumatology, Boston University School of Medicine, Boston, MA, 7Massachusetts General Hospital, Boston, MA

    Background/Purpose Autotaxin (ATX) is an enzyme present in biological fluids that is responsible for the production of the lipid mediator, lysophosphatidic acid (LPA). We previously…
  • Abstract Number: 1725 • 2014 ACR/ARHP Annual Meeting

    The SYK Inhibitor Fostamatinib Limits Tissue Damage and Fibrosis in a Bleomycin-Induced Scleroderma MOUSE MODEL

    Omer Nuri Pamuk1, Guray Can2, Suleyman Ayvaz3, Turan Karaca4, Gulsum Pamuk5, Selim Demirtas6 and George C. Tsokos7, 1Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, 2Gastroenterology, Trakya University Medical Faculty, Edirne, Turkey, 3Pediatric Surgery, Trakya University Medical Faculty, Edirne, Turkey, 4Histology, Trakya University Medical Faculty, Edirne, Turkey, 5Hematology, Trakya University Medical Faculty, Edirne, Turkey, 6Trakya University Medical Faculty, Edirne, Turkey, 7Rheumatology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA

    Background/Purpose The possible antifibrotic effects of various kinase inhibitors has been studied before in SSc. Spleen tyrosine kinase (Syk) is a protein tyrosine kinase which…
  • Abstract Number: 969 • 2014 ACR/ARHP Annual Meeting

    Caspase-8 Prevents Lung Fibrosis in a Murine SSc-like Disease Model By Preventing Macrophage Differentiation

    Alexander Misharin1, Carla M. Cuda2, Luisa Morales-Nebreda3, Gokhan Mutlu1, GR Scott Budinger3 and Harris R. Perlman4, 1Northwestern University, Chicago, IL, 2Medicine / Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 3Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL, 4Northwestern University Feinberg School of Medicine, Chicago, IL

    Background/Purpose Pulmonary fibrosis has emerged as the leading cause of death in patients with Systemic Sclerosis (SSc). Currently available therapies are only marginally effective in…
  • Abstract Number: 964 • 2014 ACR/ARHP Annual Meeting

    Skin Collagen Synthesis Rates Distinguish Between Early and Late Diffuse Scleroderma Patients

    Claire Emson1, Martin Decaris1, Michelle Gatmaitan1, Flora Luo1, Dan Holochwost1, Simplicia FloraCruz1, Thomas Angel1, Kelvin Li1, Marc Hellerstein1, Fredrick M. Wigley2, Scott Turner1,3 and Francesco Boin2, 1KineMed Inc., Emeryville, CA, 2Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 35980 Horton Street, Suite 470, KineMed Inc., Emeryville, CA

    Background/Purpose The synthesis and degradation of extracellular matrix (ECM), particularly collagen, is one of the central mechanisms perturbed in scleroderma (SSc). Understanding the kinetics of…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology